Published in Cancer Weekly, September 16th, 2003
According to recent research from Italy, "Evaluation of treatment response is of primary importance in the management of patients with cancer. Both positron- and gamma-emitting compounds have been used to monitor changes in tumor metabolism or viability after therapy.
"The use of Tc-99m-labeled lipophilic cations raised the possibility to predict the tumor response to treatment and to identify patients who win become refractory to subsequent therapy. In particular, many studies have shown the prognostic value of Tc-99m-MIBI scan in different types of malignancy including breast and lung...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.